Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis-Reference-Cited by-同舟云学术

Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis

Published:2021-11-16 Issue:11 Volume:4 Page:e2134627
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Hou Jue¹,Kim Nicole¹,Cai Tianrun²,Dahal Kumar²,Weiner Howard³,Chitnis Tanuja³,Cai Tianxi¹⁴,Xia Zongqi⁵⁶

Affiliation:

1. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts

2. Division of Rheumatology, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts

3. Department of Neurology, Brigham and Women’s Hospital, Boston, Massachusetts

4. Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts

5. Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania

6. Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2786182/hou_2021_oi_210978_1636390122.14323.pdf

Reference48 articles.

1. Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis.;Piehl;J Intern Med,2021

2. Treatment of multiple sclerosis: a review.;Hauser;Am J Med,2020

3. Head-to-head drug comparisons in multiple sclerosis: urgent action needed.;Tur;Neurology,2019

4. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.;Fox;Curr Med Res Opin,2017

5. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.;Hersh;Mult Scler J Exp Transl Clin,2017

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-05

2. Comparing insulin vs GLP-1 RA, DPP4I, SGLT2I on 5-year incident heart failure for patients with type 2 diabetes mellitus: a real-world evidence study using insurance claims (Preprint);JMIR Diabetes;2024-03-07

3. Comparing insulin vs GLP-1, DPP-4, SGLT-2 on 5-year incident heart failure for patients with type 2 diabetes mellitus: a real-world evidence study using insurance claims (Preprint);2024-03-07

4. Relationships between indices of cognitive reserve and cognitive impairment in patients with multiple sclerosis;Current Psychology;2024-01-23

5. LATTE: Label-efficient incident phenotyping from longitudinal electronic health records;Patterns;2024-01